DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: Community Center
Online groups, photo galleries and blogs
The Role of Sleep Impairments on Pain Severity in Adults With Sickle Cell Disease
Sleep is a complex process and impairments can occur at different stages of the process. Sleep impairments may include decreased total sleep time (sleep duration), an increase in the amount of time it takes to fall asleep (sleep onset latency), or an increase in the amount of wakefulness after sleep onset (sleep fragmentation) experienced by an individual (Mezick, 2013).
Studies broadly suggest that sleep impairments can be directly linked to increased pain (Finan, 2013) and it is this relationship that our group chose to explore further in adults with sickle cell disease (SCD) (Moscou-Jackson, 2015).
Related Content
-
education & researchInflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemiaChildren with sickle cell anemia (SCA) s...
-
education & researchContraceptive Methods and the Impact of Menstruation on Daily Functioning in Women With Sickle Cell DiseaseObjectives: Women with sickle cell dise...
-
news & eventsVirtual Reality Helps Reduce Pain Among Patients With Sickle Cell DiseaseImmersive virtual reality appeared effec...
-
news & eventsOrphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
-
news & eventsHow sickled red blood cells stick to blood vesselsOne of the most common complications o...
-
news & eventsSickle Cell Disease and Cold Weather: Dos and Don’tsIn the United States today, one of every...
-
news & eventsGBT expands sickle cell disease pipeline with worldwide licensing agreement for inclacumab for the treatment of vaso...Global Blood Therapeutics, Inc...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.